BR0317593A - Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase - Google Patents

Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase

Info

Publication number
BR0317593A
BR0317593A BR0317593-6A BR0317593A BR0317593A BR 0317593 A BR0317593 A BR 0317593A BR 0317593 A BR0317593 A BR 0317593A BR 0317593 A BR0317593 A BR 0317593A
Authority
BR
Brazil
Prior art keywords
hmg
inhibitor
coa reductase
reductase inhibitor
dosage forms
Prior art date
Application number
BR0317593-6A
Other languages
English (en)
Inventor
Dwayne Thomas Friesen
Douglas Alan Lorenz
David Keith Lyon
Bruno Caspar Hancock
Timothy Joseph Mcdermott
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0317593(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0317593A publication Critical patent/BR0317593A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMAS DE DOSAGEM COMPREENDENDO UM INIBIDOR DE CETP E UM INIBIDOR DE HMG-COA REDUCTASE" Uma forma de dosagem compreende (1) uma dispersão sólida amorfa compreendendo um inibidor de proteina de transferência de éster colesterílico e um polímero que aumenta a concentração ácida e (2) um inibidor de HMG-CoA reductase. A dispersão sólida amorfa e o inibidor de HMG-CoA reductase são combinados na forma de dosagem de modo tal, que a dispersão sólida amorfa e o inibidor de HMG-CoA reductase se encontram substancialmente separados entre si.
BR0317593-6A 2002-12-20 2003-12-12 Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase BR0317593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43534502P 2002-12-20 2002-12-20
PCT/IB2003/006087 WO2004056359A1 (en) 2002-12-20 2003-12-12 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor

Publications (1)

Publication Number Publication Date
BR0317593A true BR0317593A (pt) 2005-11-22

Family

ID=32682223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317593-6A BR0317593A (pt) 2002-12-20 2003-12-12 Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase

Country Status (24)

Country Link
US (1) US7897175B2 (pt)
EP (1) EP1581210B1 (pt)
JP (1) JP2006512359A (pt)
KR (1) KR20050088190A (pt)
CN (1) CN1728995A (pt)
AR (1) AR042534A1 (pt)
AT (1) ATE389396T1 (pt)
AU (1) AU2003286372A1 (pt)
BR (1) BR0317593A (pt)
CA (1) CA2509688A1 (pt)
CO (1) CO5590898A2 (pt)
DE (1) DE60319877T2 (pt)
ES (1) ES2300628T3 (pt)
GT (1) GT200300295A (pt)
IL (1) IL169090A0 (pt)
NL (1) NL1025070C (pt)
NO (1) NO20052779L (pt)
PE (1) PE20040970A1 (pt)
PL (1) PL377606A1 (pt)
RU (1) RU2005119176A (pt)
TW (1) TW200420301A (pt)
UY (1) UY28134A1 (pt)
WO (1) WO2004056359A1 (pt)
ZA (1) ZA200504123B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8828438B2 (en) 2005-05-31 2014-09-09 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase
PL1912626T3 (pl) * 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
KR100791256B1 (ko) * 2006-03-17 2008-01-03 주식회사 대웅제약 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
WO2008065506A2 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles comprising enteric polymers and casein
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
US10300059B2 (en) * 2014-08-28 2019-05-28 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
ATE226826T1 (de) * 1995-06-01 2002-11-15 Searle & Co Misoprostolhaltige feste stabilisierte dispersionen
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
AU4943400A (en) * 2000-06-09 2001-12-17 Lek Tovarna Farmacevtskih Stabilized pharmaceutically effective composition and pharmaceutical formulationcomprising the same
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AP2003002743A0 (en) * 2000-08-15 2003-03-31 Pfizer Prod Inc Therapeutic combination of a cept inhibitor and atorvastatin
US20020077348A1 (en) 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
CA2450238A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US20040132771A1 (en) 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor

Also Published As

Publication number Publication date
GT200300295A (es) 2004-08-18
DE60319877D1 (de) 2008-04-30
ATE389396T1 (de) 2008-04-15
ES2300628T3 (es) 2008-06-16
JP2006512359A (ja) 2006-04-13
ZA200504123B (en) 2006-02-22
NO20052779L (no) 2005-08-25
WO2004056359A1 (en) 2004-07-08
US7897175B2 (en) 2011-03-01
AR042534A1 (es) 2005-06-22
RU2005119176A (ru) 2006-01-20
AU2003286372A1 (en) 2004-07-14
CN1728995A (zh) 2006-02-01
PE20040970A1 (es) 2004-12-14
US20040197398A1 (en) 2004-10-07
CO5590898A2 (es) 2005-12-30
NL1025070A1 (nl) 2004-06-22
TW200420301A (en) 2004-10-16
IL169090A0 (en) 2007-07-04
EP1581210A1 (en) 2005-10-05
PL377606A1 (pl) 2006-02-06
UY28134A1 (es) 2004-07-30
EP1581210B1 (en) 2008-03-19
DE60319877T2 (de) 2009-04-30
NO20052779D0 (no) 2005-06-08
NL1025070C (nl) 2010-04-06
KR20050088190A (ko) 2005-09-02
CA2509688A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
BR0317593A (pt) Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase
WO2005065182A3 (en) Optical retarders and related devices and systems
AU2003259126A1 (en) Providing advertising over the internet
AU2001274078A1 (en) Prepolymeric (meth)acrylates with polycyclic or aromatic segments
IL164021A0 (en) Antibodies and anti-pharmaceutical compositions containing the same
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CA2446539A1 (en) System and method for electronic presentations
AU2003299778A1 (en) Antibodies against gpr64 and uses thereof
AU2003227263A1 (en) Phosphor and phosphor composition containing the same
IL172598A0 (en) Antibodies specific for sclerostin and pharmaceutical compositions containing the same
BR0215405A (pt) Composições e processos de uso de collajolie
AU2003303255A1 (en) Optical substrate, display device using the same and their manufacturing methods
WO2003102012A3 (en) New etonogestrel esters
ATE326968T1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
AU2003215175A1 (en) Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof
HRP20080612T3 (hr) Kombinacija tenofovira, ritonavira i tmc114
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
AUPS111502A0 (en) Anonymous gifting
WO2003087051A3 (en) Methods for identifying allosteric sites
AU2003303074A1 (en) Sphingolipid derivatives modified by polyethylene glycol and composition containing the same
AU2002950171A0 (en) Advertising device
AU2003211957A1 (en) Curable resin and curable resin composition containing the same
AU2003289523A1 (en) Advertising method using the internet transporter
AU2003296820A1 (en) Epitopic peptides of the thyroperoxidase enzyme, compositions containing same and uses thereof
ES1051849Y (es) Aerostato publicitario.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.